NovImmune Company Profile

News Articles [ 9 Associated News Articles listed on BioPortfolio]

NovImmune receives EC grant for NI-0501 development

The European Commission (EC) has granted a €6m grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.

FIGHT HLH Consortium receives EUR 6 million FP7 grant for testing NovImmune's NI-0501

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gam...

NovImmune Initiates Phase I Clinical Study with First-in-Class Anti-TLR4 Monoclonal Antibody

NovImmune SA initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4). NI-0101 was discovered a...

NovImmune hematology news

NovImmune Strengthens Board and Management Team

NovImmune SA announced the addition of Michael Steinmetz, Ph.D. to its Board of Directors and David Slack as Head of Corporate & Business Development Dr. Stein...

European Commission Awards a EUR 6 Million FP7 Grant to Support Clinical Development of NI-0501 to FIGHT HLH

NovImmune SA announced that the European Commission has awarded a 6 million Euros FP7 grant to the “FIGHT HLH” consortium of institutions to support clinical testing of...

NovImmune's orphan drug candidate wins $7.8M grant

A consortium of European researchers received a grant worth about $7.8 million from the European Commission to fund clinical  -More- 

Congratualtions to Red Herring's 2012 top 100 European award winners - Abionic SA, AlphaSIP, BONESUPPORT AB, Morflora, NovImmune SA, StereoTools SA, CERENIS THERAPEUTICS, Miracor Medical Systems, Modz Ltd, Relaxbirth Ltd.

The Red Herring editorial team selected six Biosciences - Biomedical and four Life Science companies in their 2012 Top 100 European Technology Companies. This exceptional group of companies...

Drugs and Medications [0 Results]

None

PubMed Articles [ 3 Associated PubMed Articles listed on BioPortfolio]

By-passing in vitro screening--next generation sequencing technologies applied to antibody display and in silico candidate selection.

In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library d...

Toll-like Receptor 4 Signaling by Follicular Dendritic Cells Is Pivotal for Germinal Center Onset and Affinity Maturation.

Germinal centers (GCs) are specialized microenvironments where antigen-activated B cells undergo proliferation, immunoglobulin (Ig) class switch recombination, somatic hypermutation (SHM), and affinit...

Pan-CC Chemokine Neutralization Restricts Splenocyte Egress and Reduces Inflammation in a Model of Arthritis.

Chemokines are key regulators of leukocyte trafficking and play a crucial role under homeostatic and inflammatory conditions. Because chemokines are involved in multiple pathologies, they represent an...

Clinical Trials [0 Results]

None

Companies [ 2 Associated Companies listed on BioPortfolio]

NovImmune

NovImmune SA ('NovImmune') is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders.

NovImmune SA

NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. NovImmune...